Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer's disease

Armstrong, Paul and Güngör, Hüseyin and Anongjanya, Pariya and Tweedy, Clare and Parkin, Edward and Johnston, Jamie and Carr, Ian M and Dawson, Neil and Clapcote, Steven J (2024) Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer's disease. Neuropsychopharmacology, 49 (10). pp. 1559-1568. ISSN 0893-133X

[thumbnail of Armstrong et al., 2024]
Text (Armstrong et al., 2024)
Armstrong_et_al._2024.pdf - Published Version
Available under License Creative Commons Attribution.

Download (3MB)

Abstract

Meta-analysis of genome-wide association study data has implicated PDE4B in the pathogenesis of Alzheimer's disease (AD), the leading cause of senile dementia. PDE4B encodes one of four subtypes of cyclic adenosine monophosphate (cAMP)-specific phosphodiesterase-4 (PDE4A-D). To interrogate the involvement of PDE4B in the manifestation of AD-related phenotypes, the effects of a hypomorphic mutation (Pde4bY358C) that decreases PDE4B's cAMP hydrolytic activity were evaluated in the AppNL-G-F knock-in mouse model of AD using the Barnes maze test of spatial memory, 14C-2-deoxyglucose autoradiography, thioflavin-S staining of β-amyloid (Aβ) plaques, and inflammatory marker assay and transcriptomic analysis (RNA sequencing) of cerebral cortical tissue. At 12 months of age, AppNL-G-F mice exhibited spatial memory and brain metabolism deficits, which were prevented by the hypomorphic PDE4B in AppNL-G-F/Pde4bY358C mice, without a decrease in Aβ plaque burden. RNA sequencing revealed that, among the 531 transcripts differentially expressed in AppNL-G-F versus wild-type mice, only 13 transcripts from four genes - Ide, Btaf1, Padi2, and C1qb - were differentially expressed in AppNL-G-F/Pde4bY358C versus AppNL-G-F mice, identifying their potential involvement in the protective effect of hypomorphic PDE4B. Our data demonstrate that spatial memory and cerebral glucose metabolism deficits exhibited by 12-month-old AppNL-G-F mice are prevented by targeted inhibition of PDE4B. To our knowledge, this is the first demonstration of a protective effect of PDE4B subtype-specific inhibition in a preclinical model of AD. It thus identifies PDE4B as a key regulator of disease manifestation in the AppNL-G-F model and a promising therapeutic target for AD.

Item Type:
Journal Article
Journal or Publication Title:
Neuropsychopharmacology
Uncontrolled Keywords:
Research Output Funding/yes_externally_funded
Subjects:
?? yes - externally fundednogeneral medicinemedicine(all) ??
ID Code:
216966
Deposited By:
Deposited On:
25 Mar 2024 11:20
Refereed?:
Yes
Published?:
Published
Last Modified:
26 Nov 2024 02:09